Alison M. Binder

Alison M. Binder

Auto-generated profile, based on publicly available information

Alison M. Binder

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Open access
ABAlison M. Binder
Alison M. Binder
SCScott P. Commins
Scott P. Commins
MAMichelle L. Altrich
Michelle L. Altrich
TWTyler Wachs
Tyler Wachs
BBBrad J. Biggerstaff
Brad J. Biggerstaff
PAPaige A. Armstrong
Paige A. Armstrong
Alpha-gal syndrome (AGS) is an emerging immunoglobulin E (IgE)-mediated allergy to galactose-alpha-1,3-galactose (alpha-gal). The geographic distribution and burden of AGS in the United States are unknown. To characterize alpha-gal IgE testing patterns and describe the trends and distribution from 2010 to 2018 in the United States. This retrospective analysis included all persons tested for alpha-gal IgE antibodies by Viracor-IBT Laboratories (Lee's Summit, Missouri), the primary site of testing in the United States. Data included age and sex of person tested, specimen state of origin, collection date, and result value; persons with at least 1 positive test result (≥0.1 kU/L) were compared with negatives. Proportions tested and with positive test results were calculated using the US Census population estimates. Overall, 122,068 specimens from 105,674 persons were tested for alpha-gal IgE during July 1, 2010, to December 31, 2018. Nearly one-third (34,256, 32.4%) had at least 1 positive result. The number of persons receiving positive test results increased 6-fold from 1110 in 2011 to 7798 in 2018. Of those receiving positive test results, mean [SD] age was 46.9 (19.8) years; men were more likely to test positive than women (43.3% vs 26.0%). Arkansas, Virginia, Kentucky, Oklahoma, and Missouri had the highest number of persons who were tested and had a positive result per 100,000 population. More than 34,000 persons, most presumably symptomatic, have received positive test results for IgE antibodies to alpha-gal, suggesting AGS is an increasingly recognized public health problem. The geographic distribution of persons who tested positive is consistent with exposure to Amblyomma americanum ticks.

6 January 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
DÁDiego I. Álvarez-López
Diego I. Álvarez-López
EOEstefanía Ochoa-Mora
Estefanía Ochoa-Mora
KHKristen Nichols Heitman
Kristen Nichols Heitman
ABAlison M. Binder
Alison M. Binder
GAGERARDO ALVAREZ
GERARDO ALVAREZ
PAPaige A. Armstrong
Paige A. Armstrong
Rocky Mountain spotted fever (RMSF), caused by Rickettsia rickettsii, is a severe and potentially fatal tick-borne disease. In 2015, Mexico issued a declaration of epidemiologic emergency in response to ongoing outbreaks of RMSF in northern Mexico. Sonora state is one of the most heavily impacted states in Mexico, with historic case fatality rates (CFRs) of 18%. We summarized data from enhanced surveillance to understand demographic, clinical, and treatment factors associated with the high mortality. We conducted a retrospective review of confirmed and probable RMSF cases reported to the General Directorate of Health Promotion and Disease Prevention in Sonora. A case of RMSF is defined as fever (> 38.5°C), plus two symptoms, and epidemiologic criteria. A confirmed case requires laboratory evidence. During 2015–2018, a total of 510 cases of RMSF were reported; 252 (49%) were in persons aged ≤ 18 years. Case fatality rate was 44% (n = 222). Older age and being confirmed by PCR were associated with fatal outcome (P-value < 0.01). The mean time from onset of symptoms to treatment with doxycycline was 7.9 days (SD ± 5.5). Hot spot analysis revealed neither areas of inordinately high nor low incidence, rather clusters of disease in population centers. The CFR for RMSF in Sonora remains high, and a large proportion of cases are seen in persons aged ≤ 18 years. Whereas previously children experienced a disproportionately high CFR, interventions have reversed this trend. Disease clusters in urban nuclei, but location remains a predictor of fatal outcome.

14 October 2022 in Allergy
Verified
Journal Article
Open access
ABAlison M. Binder
Alison M. Binder
DCDena Cherry‐Brown
Dena Cherry‐Brown
BBBrad J. Biggerstaff
Brad J. Biggerstaff
EJEmma S. Jones
Emma S. Jones
CAClaire L. Amelio
Claire L. Amelio
PAPaige A. Armstrong
Paige A. Armstrong
Background: Alpha‐gal syndrome (AGS) is an IgE‐mediated allergy to galactose‐alpha‐1,3‐galactose. Clinical presentation ranges from hives to anaphylaxis; episodes typically occur 2–6 h after exposure to alpha‐gal‐containing products. In the United States, lone star tick bites are associated with the development of AGS. To characterize features of AGS, we evaluated a cohort of patients presenting for care at the University of North Carolina, focusing on symptoms, severity, and identifying features unique to specific alpha‐gal‐containing product exposures.Methods: We performed a chart review and descriptive analysis of 100 randomly selected patients with AGS during 2010–2019.Results: Median age at onset was 53 years, 56% were female, 95% reported White race, 86% reported a history of tick bite, and 75% met the criteria for anaphylaxis based on the involvement of ≥2 organ systems. Those reporting dairy reactions were significantly less likely to report isolated mucocutaneous symptoms (3% vs. 24%; ratio [95% CI]: 0.1 [0.1, 0.3]) than those who tolerated dairy, and were more likely to report gastrointestinal symptoms (79% vs. 59%; ratio [95% CI]: 1.3 [0.7, 2.6]), although this difference was not statistically significant. Dairy‐tolerant patients demonstrated higher alpha‐gal sIgE titers (as a percentage of total IgE) than dairy‐reactive patients (GM 4.1 [95% CI: 2.7, 6.1] vs. GM 2.5 [95% CI: 1.3, 4.8], respectively; ratio −1.6 [95% CI: −1.0, 3.9]).Conclusion: While tick exposure is common in the southern United States, nearly all AGS patients reported a tick bite. Gastrointestinal symptoms were prominent among those reporting reactions to dairy. Anaphylaxis was common, underscoring the severity and need to raise awareness of AGS among patients and providers.

6 November 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
UKUzay Kırbıyık
Uzay Kırbıyık
ABAlison M. Binder
Alison M. Binder
IGIsaac Ghinai
Isaac Ghinai
CZChad Zawitz
Chad Zawitz
RLRebecca Levin
Rebecca Levin
PAPaige A. Armstrong
Paige A. Armstrong
This report describes analyses of network characteristics of a COVID-19 outbreak in a detention facility.

15 March 2019 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
ABAlison M. Binder
Alison M. Binder
KHKristen Nichols Heitman
Kristen Nichols Heitman
NDNaomi A. Drexler
Naomi A. Drexler
A total of 16,807 spotted fever rickettsioses supplemental case report forms were provided to CDC with illness onset during 2010–2015; 1.0% met criteria for confirmation. Reasons for nonconfirmation included failure to submit a second serum specimen and low utilization of molecular diagnostic techniques.

12 November 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HMHalie K. Miller
Halie K. Miller
ABAlison M. Binder
Alison M. Binder
APAmy Peterson
Amy Peterson
ETElitza S. Theel
Elitza S. Theel
JVJoseph M. Volpe
Joseph M. Volpe
GKGilbert J. Kersh
Gilbert J. Kersh
Laboratory testing for Q fever (Coxiella burnetii) is essential for a differential diagnosis, yet little is known about Q fever diagnostic testing practices in the United States. We retrospectively analyzed Q fever immunoglobulin G (IgG) indirect immunofluorescence assay (IFA) testing data between 1/1/2012–10/31/2016 from ARUP, LabCorp, Mayo Medical Laboratories, and Quest Diagnostics. Data included IgG phase I and phase II titers, patient age and sex, and state and date of specimen collection. On average, 12,821 specimens were tested for Q fever annually by the participating laboratories. Of 64,106 total specimens, 84.1% tested negative for C. burnetii-specific antibodies. Positive titers ranged from 16 to 262,144 against both phase I and phase II antigens. Submission of specimens peaked during the summer months, and more specimens were submitted from the West North Central division. Testing occurred more frequently in males (53%) and increased with age. In conclusion, few U.S. Q fever cases are reported, despite large volumes of diagnostic specimens tested. Review of commercial laboratory data revealed a lack of paired serology samples and patterns of serology titers that differ from case reporting diagnostic criteria.